JP2014195454A5 - - Google Patents

Download PDF

Info

Publication number
JP2014195454A5
JP2014195454A5 JP2014087047A JP2014087047A JP2014195454A5 JP 2014195454 A5 JP2014195454 A5 JP 2014195454A5 JP 2014087047 A JP2014087047 A JP 2014087047A JP 2014087047 A JP2014087047 A JP 2014087047A JP 2014195454 A5 JP2014195454 A5 JP 2014195454A5
Authority
JP
Japan
Prior art keywords
peptide
receptor
polypeptide
protease
hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014087047A
Other languages
English (en)
Other versions
JP2014195454A (ja
JP5891258B2 (ja
Filing date
Publication date
Priority claimed from GB0810785A external-priority patent/GB0810785D0/en
Priority claimed from GBGB0810782.3A external-priority patent/GB0810782D0/en
Priority claimed from GB0820884A external-priority patent/GB0820884D0/en
Priority claimed from GB0820965A external-priority patent/GB0820965D0/en
Application filed filed Critical
Publication of JP2014195454A publication Critical patent/JP2014195454A/ja
Publication of JP2014195454A5 publication Critical patent/JP2014195454A5/ja
Application granted granted Critical
Publication of JP5891258B2 publication Critical patent/JP5891258B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (14)

  1. 先端巨大症の治療に使用するためのポリペプチドであって、
    a.下垂体腫瘍細胞におけるエキソサイトーシス融合装置のタンパク質を切断することができる非細胞傷害性プロテアーゼ、
    b.エンドサイトーシスを受けて、下垂体腫瘍細胞内のエンドソームに組み込まれ得る、前記下垂体腫瘍細胞上の結合部位に結合するペプチドターゲティング部分(TM)、及び
    c.エンドソームの内部からエンドソーム膜を通過して前記下垂体腫瘍細胞の細胞質ゾル中に前記プロテアーゼを移行させる細菌又はウイルスの移行ドメイン
    を含み、
    クロストリジウムの神経毒の天然H CC 結合ドメインを欠如する
    ポリペプチド。
  2. 下垂体腫瘍細胞が、ソマトトロピノーマに由来する、又はそれの原因となる、請求項1に記載のポリペプチド。
  3. TMが、成長ホルモン放出ホルモン(GHRH)受容体;ソマトスタチン(SST)受容体、コルチスタチン(CST)受容体;グレリン受容体;ボンベシン受容体;ウロテンシン受容体;メラニン凝集ホルモン受容体1;KiSS−1受容体;ゴナドトロピン放出ホルモン(GnRH)受容体;及び/又は、プロラクチン放出ペプチド受容体を含む群から選択される受容体に結合する、請求項1又は2に記載のポリペプチド。
  4. TMが、成長ホルモン放出ホルモン(GHRH)ペプチド、ソマトスタチンペプチド、コルチスタチンペプチド、グレリンペプチド、ボンベシンペプチド、ウロテンシンペプチド、メラニン凝集ホルモンペプチド、KISS−1ペプチド、ゴナドトロピン放出ホルモン(GnRH)ペプチド、又はプロラクチン放出ペプチドを含む、請求項1〜3のいずれかに記載のポリペプチド。
  5. 非細胞傷害性プロテアーゼが、クロストリジウムの神経毒L鎖又はIgAプロテアーゼを含む、請求項1〜4のいずれかに記載のポリペプチド。
  6. 移行ドメインが、クロストリジウムの神経毒移行ドメインを含む、請求項1〜5のいずれかに記載のポリペプチド。
  7. a.下垂体腫瘍細胞におけるエキソサイトーシス融合装置のタンパク質を切断することができる非細胞傷害性プロテアーゼ、
    b.エンドサイトーシスを受けて、下垂体腫瘍細胞内のエンドソームに組み込まれ得る、前記下垂体腫瘍細胞上の結合部位に結合するペプチドターゲティング部分(TM)、及び
    c.エンドソームの内部からエンドソーム膜を通過して前記下垂体腫瘍細胞の細胞質ゾル中に前記プロテアーゼを移行させる細菌又はウイルスの移行ドメイン
    を含み、
    クロストリジウムの神経毒の天然H CC 結合ドメインを欠如し、
    配列番号7、8、9、10、11、12、13、14、15、16、18、19、20、21、22、23、24、26、27、28、29、30、31、33、34、35、36、37、38、39、40、41、42、43、44、45、46、47、48、57、58、59、60、61、62、63、64、65、66、67、68、69、70、71、72、73、74、75、76、77、78、79、80、81、82、83、84、85、86、87、88、89、90、91、92、93、又は94のいずれか1つに対して、少なくとも90〜92%、又は少なくとも95〜97%、又は少なくとも98〜99%の配列同一性を有するアミノ酸配列を含む
    ポリペプチド。
  8. TMが、成長ホルモン放出ホルモン(GHRH)受容体;ソマトスタチン(SST)受容体、コルチスタチン(CST)受容体;グレリン受容体;ボンベシン受容体(例えばBRS−1、BRS−2、若しくはBRS−3);ウロテンシン受容体(例えばウロテンシンII受容体);メラニン凝集ホルモン受容体1;KiSS−1受容体;ゴナドトロピン放出ホルモン(GnRH)受容体;及び/又はプロラクチン放出ペプチド受容体を含む群から選択される受容体に結合する、請求項7に記載のポリペプチド。
  9. TMが、成長ホルモン放出ホルモン(GHRH)ペプチド、ソマトスタチンペプチド、コルチスタチンペプチド、グレリンペプチド、ボンベシンペプチド、ウロテンシンペプチド、メラニン凝集ホルモンペプチド、KISS−1ペプチド、ゴナドトロピン放出ホルモン(GnRH)ペプチド、又はプロラクチン放出ペプチドを含む、請求項7又は8に記載のポリペプチド。
  10. 移行ドメインが、クロストリジウムの神経毒移行ドメインを含み、及び/又は非細胞傷害性プロテアーゼが、クロストリジウムの神経毒プロテアーゼ若しくはIgAプロテアーゼを含む、請求項7〜9のいずれかに記載のポリペプチド。
  11. 請求項7〜10のいずれかに記載のポリペプチドをコードする核酸。
  12. 配列番号17又は25のいずれか1つに対して、少なくとも90〜94%、又は少なくとも95〜97%又は少なくとも98〜99%の配列同一性を有する核酸配列を含む、請求項11に記載のポリペプチドをコードする核酸。
  13. 非細胞傷害性プロテアーゼ成分と移行成分の間に位置する認識部位(切断部位)でポリペプチドを切断するプロテアーゼと、ポリペプチドとを接触させること、及び前記ポリペプチドを二重鎖ポリペプチドに変換することを含み、前記非細胞傷害性プロテアーゼ成分及び前記移行成分が、ジスルフィド結合によってともに結合される、請求項5に記載のポリペプチドを活性化させる方法。
  14. 請求項13の方法によって得ることができる二重鎖ポリペプチド。
JP2014087047A 2008-06-12 2014-04-21 神経内分泌疾患の抑制 Expired - Fee Related JP5891258B2 (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB0810782.3 2008-06-12
GB0810785A GB0810785D0 (en) 2008-06-12 2008-06-12 Suppression of neuroendocrine diseases
GBGB0810782.3A GB0810782D0 (en) 2008-06-12 2008-06-12 Suppression of cancers
GB0810785.6 2008-06-12
GB0820884A GB0820884D0 (en) 2008-11-14 2008-11-14 Suppression of neuroendocrine diseases
GB0820884.5 2008-11-14
GB0820965.2 2008-11-17
GB0820965A GB0820965D0 (en) 2008-11-17 2008-11-17 Suppression of cancers

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011513056A Division JP5728380B2 (ja) 2008-06-12 2009-06-11 神経内分泌疾患の抑制

Publications (3)

Publication Number Publication Date
JP2014195454A JP2014195454A (ja) 2014-10-16
JP2014195454A5 true JP2014195454A5 (ja) 2014-11-27
JP5891258B2 JP5891258B2 (ja) 2016-03-22

Family

ID=41417177

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011513056A Active JP5728380B2 (ja) 2008-06-12 2009-06-11 神経内分泌疾患の抑制
JP2014087047A Expired - Fee Related JP5891258B2 (ja) 2008-06-12 2014-04-21 神経内分泌疾患の抑制

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011513056A Active JP5728380B2 (ja) 2008-06-12 2009-06-11 神経内分泌疾患の抑制

Country Status (12)

Country Link
US (1) US20110171191A1 (ja)
EP (3) EP2310028B1 (ja)
JP (2) JP5728380B2 (ja)
KR (1) KR101642363B1 (ja)
CN (2) CN102112145B (ja)
AU (1) AU2009259033B2 (ja)
BR (1) BRPI0915888E2 (ja)
CA (1) CA2727082C (ja)
ES (2) ES2614990T3 (ja)
IL (1) IL209855A (ja)
WO (1) WO2009150469A2 (ja)
ZA (1) ZA201008536B (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101730708B (zh) 2007-03-28 2013-09-18 哈佛大学校长及研究员协会 缝合多肽
US10466245B2 (en) 2008-02-20 2019-11-05 The Secretary Of State For Health Covalently linked thermostable kinase for decontamination process validation
GB0803068D0 (en) 2008-02-20 2008-03-26 Health Prot Agency Cross-linked biological indicator
US20110171191A1 (en) * 2008-06-12 2011-07-14 Syntaxin Limited Suppression of neuroendocrine diseases
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
GB201108108D0 (en) * 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
WO2013059525A1 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
CN108912211A (zh) 2012-02-15 2018-11-30 爱勒让治疗公司 三唑交联的和硫醚交联的拟肽大环化合物
SG11201404648PA (en) 2012-02-15 2014-09-26 Aileron Therapeutics Inc Peptidomimetic macrocycles
EP2914256B1 (en) 2012-11-01 2019-07-31 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
EP3194618B1 (en) * 2014-09-15 2021-04-21 Clifton Life Sciences LLC Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US20170326166A1 (en) * 2014-10-17 2017-11-16 University Of Virginia Patent Foundation Compositions and methods for treating pituitary tumors
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
TW201814045A (zh) 2016-09-16 2018-04-16 英商艾普森生物製藥有限公司 製造雙鏈梭狀芽孢桿菌神經毒素之方法
EP3519430A1 (en) 2016-09-29 2019-08-07 Ipsen Biopharm Limited Hybrid neurotoxins
EP3312290A1 (en) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
EP3375871A1 (en) * 2017-03-13 2018-09-19 SIT Biotech GmbH Selective cell death-inducing enzyme system
JOP20190276A1 (ar) * 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة
CA3083083A1 (en) 2018-01-29 2019-08-01 Ipsen Biopharm Limited Non-neuronal snare-cleaving botulinum neurotoxins
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
CN110801512B (zh) * 2019-11-15 2023-07-18 中国水产科学研究院黑龙江水产研究所 一种用于促进哲罗鲑性腺成熟的多肽及其应用
CN111388651B (zh) * 2020-05-09 2022-05-03 山东大学齐鲁医院 Cst-14在制备骨质疏松症治疗药物中的应用
CN113257370B (zh) * 2021-05-12 2022-09-02 中国医学科学院北京协和医院 基于临床病理基本信息和vista检测的pnet复发风险预测模型

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291022A (en) 1975-03-11 1981-09-22 Sandoz Ltd. Organic compounds
US4133782A (en) 1976-06-07 1979-01-09 The Salk Institute For Biological Studies Somatostatin analogs with dissociated biological activities
US4190575A (en) 1977-12-27 1980-02-26 American Home Products Corporation Polypeptides related to somatostatin
DE2860734D1 (en) 1977-06-08 1981-09-03 Merck & Co Inc Somatostatin analogs, process for their preparation and pharmaceutical compositions containing them
US4211693A (en) 1977-09-20 1980-07-08 The Salk Institute For Biological Studies Peptides with para-substituted phenylalanine
LU78191A1 (de) 1977-09-28 1979-05-25 Ciba Geigy Ag Verfahren zur herstellung von neuen cyclopeptiden
JPS5819669B2 (ja) 1978-10-28 1983-04-19 白井松新薬株式会社 新規生理活性ペプチド化合物及びその製造法
US4190648A (en) 1979-03-13 1980-02-26 Merck & Co., Inc. Peptides having somatostatin activity
US4316890A (en) 1979-03-16 1982-02-23 Ciba-Geigy Corporation Peptides and processes for the manufacture thereof
US4328214A (en) 1979-07-04 1982-05-04 Ciba-Geigy Corporation Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture
US4310518A (en) 1979-10-31 1982-01-12 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
US4235886A (en) 1979-10-31 1980-11-25 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
US4369179A (en) 1979-12-14 1983-01-18 Ciba-Geigy Corporation Acylpeptides
US4282143A (en) 1980-06-13 1981-08-04 American Home Products Corporation Octapeptides lowering growth hormone
US4360516A (en) 1981-04-13 1982-11-23 Merck & Co., Inc. Modified D-retro cyclic hexapeptide somatostatin analogs
ATE14226T1 (de) 1981-12-24 1985-07-15 Ciba Geigy Ag Cyclische octapeptide und pharmazeutische praeparate davon, sowie verfahren zur herstellung derselben und ihre anwendung.
FR2522655B1 (fr) 1982-03-05 1987-03-06 Sanofi Sa Analogues de la somatostatine possedant une liaison du type hydrazide et medicaments en contenant
US4522813A (en) 1983-10-27 1985-06-11 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
US4659693A (en) 1984-04-30 1987-04-21 Syntex (U.S.A.) Inc. N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides
US4632979A (en) 1984-06-18 1986-12-30 Tulane Educational Fund Therapeutic LHRH analogs
US4684620A (en) 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
US5003011A (en) 1985-04-09 1991-03-26 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4650787A (en) 1985-04-25 1987-03-17 Schally Andrew Victor Biologically active octapeptides
US4725577A (en) 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
US4585755A (en) 1985-04-29 1986-04-29 Merck & Co., Inc. Cyclic and bridged cyclic somatostatin analogs useful as local anti-inflammatory agents
US4904642A (en) 1985-09-12 1990-02-27 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4853371A (en) 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4803261A (en) 1986-06-27 1989-02-07 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide
NL194729C (nl) 1986-10-13 2003-01-07 Novartis Ag Werkwijze voor de bereiding van peptidealcoholen via vaste fase.
US4871717A (en) 1987-01-07 1989-10-03 Administrators Of The Tulane Educational Fund Peptides
JP2795449B2 (ja) 1987-09-24 1998-09-10 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド 治療用ペプチド
US5084555A (en) 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
AU632468B2 (en) 1988-02-01 1993-01-07 Upjohn Company, The Renin inhibiting peptides with polar end groups
ZA895838B (en) 1988-08-18 1991-03-27 Syntex Inc Pharmaceutical compounds
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
HU208439B (en) 1988-10-14 1993-10-28 Univ Tulane Process for producing pharmaceutical peptides
US5171835A (en) 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
CA2012115C (en) 1989-03-15 2001-07-03 Biomeasure, Inc. Iodinated somatostatins
CA2053250A1 (en) 1989-04-26 1990-10-27 David H. Coy Linear somatostatin analogs
WO1991009056A1 (en) 1989-12-08 1991-06-27 The Administrators Of The Tulane Educational Fund Octapeptide analogs of somatostatin having threonine at the sixth position
DK0450461T3 (da) 1990-04-06 1995-10-23 Univ Tulane LHRH-analoger
EP0527914A4 (en) 1990-05-04 1993-08-11 The Administrators Of The Tulane University Educational Fund Novel synthetic grf analogs
HUT62604A (en) 1990-05-09 1993-05-28 Univ Tulane Process for producing peptides for treating tissue proliferation and pharmaceutical compositions comprising same
IT1240643B (it) 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
HU207104B (en) 1991-01-25 1993-03-01 Biosignal Kutato Fejlesztoe Kf Process for producing new somatostatin analogs inhibiting tumour growth and pharmaceutical compositions comprising such compounds
US6083915A (en) 1991-05-10 2000-07-04 Biomeasure, Inc. Method for treating liver cancer
US5240561A (en) 1992-02-10 1993-08-31 Industrial Progress, Inc. Acid-to-alkaline papermaking process
AU3658093A (en) 1992-02-10 1993-09-03 Seragen, Inc. Desensitization to specific allergens
US5656727A (en) 1992-09-15 1997-08-12 The Administrators Of The Tulane Educational Fund Antagonists of LHRH
WO1994011397A1 (en) 1992-11-13 1994-05-26 The Administrators Of The Tulane Educational Fund Ghrh agonists
AU5668894A (en) 1992-11-13 1994-06-08 The Administrators Of The Tulane Eductional Fund Ghrh agonists
GB9305735D0 (en) 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
SK15096A3 (en) 1993-08-09 1996-07-03 Biomeasure Inc Therapeutic peptide derivatives and a method of their application
US5550212A (en) 1993-12-17 1996-08-27 The Administrators Of The Tulane Educational Fund Analogues of hGH-RH(1-29)NH2 having antagonistic activity
AUPM985694A0 (en) 1994-12-02 1995-01-05 Farmer, Mostyn Golf training aid
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
ES2124496T3 (es) 1995-03-13 1999-02-01 Biomeasure Inc Analogos de bombesina.
EP0820296A4 (en) 1995-04-14 1999-06-30 Univ Tulane ANALOGS OF THE GROWTH HORMONE-RELEASING FACTOR
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
US5942489A (en) 1996-05-03 1999-08-24 The Administrators Of The Tulane Educational Fund HGH-RH(1-29)NH2 analogues having antagonistic activity
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
AU3215597A (en) 1996-08-30 1998-03-19 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
US5968903A (en) 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
RU2214420C2 (ru) 1998-05-13 2003-10-20 Биотекон Гезелльшафт Фюр Биотехнологише Энтвиклунг Унд Консультинг Мбх Гибридный белок для ингибирования дегрануляции мастоцитов и его применение
DK1098664T3 (da) 1998-07-22 2003-11-17 Osprey Pharmaceuticals Ltd Sammensætninger og deres anvendelser til at behandle sekundær vævsskade og andre inflammatoriske tilstande og forstyrrelser
NZ509348A (en) 1998-07-30 2004-02-27 Sod Conseils Rech Applic Use of a somatostatin analogue Lanreotide
US20040071736A1 (en) * 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6057422A (en) 1998-11-25 2000-05-02 The Administrators Of The Tulane Educational Fund Antagonistic analogs of GH-RH inhibiting IGF-I and -II
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US6358697B2 (en) 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
AR020862A1 (es) 1999-06-04 2002-05-29 Sod Conseils Rech Applic Neuromedina b y agonistas del receptor de somatostatina
ES2277854T5 (es) * 1999-08-25 2011-02-04 Allergan, Inc. Neurotoxinas recombinantes activables.
US20080032931A1 (en) * 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
US20030180289A1 (en) * 1999-09-23 2003-09-25 Foster Keith Alan Inhibition of secretion from non-neuronal cells
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6831059B2 (en) * 2000-10-20 2004-12-14 Allergan, Inc. Compositions and methods for treating gonadotrophin related illnesses
US6827931B1 (en) * 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
WO2004076634A2 (en) * 2003-02-24 2004-09-10 Ira Sanders Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease
TW200517400A (en) * 2003-08-05 2005-06-01 Univ Tulane Antagonistic analogs of GH-RH (2003)
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
AU2005279741B2 (en) * 2004-09-01 2011-10-06 Allergan, Inc. Degradable clostridial toxins
GB0426394D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
WO2006059093A2 (en) * 2004-12-01 2006-06-08 Health Protection Agency Fusion proteins
US8399400B2 (en) * 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
GB0426397D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
CA2601577A1 (en) * 2005-03-15 2006-09-21 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
ES2369558T3 (es) 2005-09-19 2011-12-01 Allergan, Inc. Toxinas clostridiales y toxinas clostridiales activables.
EP1834962A1 (de) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
EP2038299A2 (en) 2006-07-11 2009-03-25 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
CA2658260A1 (en) * 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
JP5799397B2 (ja) * 2008-06-12 2015-10-28 イプセン・バイオイノベーション・リミテッドIpsen Bioinnovation Limited 癌の抑制
US20110171191A1 (en) * 2008-06-12 2011-07-14 Syntaxin Limited Suppression of neuroendocrine diseases
US10057187B1 (en) 2015-05-27 2018-08-21 Amazon Technologies, Inc. Dynamic resource creation to connect client resources in a distributed system

Similar Documents

Publication Publication Date Title
JP2014195454A5 (ja)
NZ599259A (en) Mycobacterial vaccines
MX2022001134A (es) Proteinas quimericas de factor viii y usos de estas.
PH12016502011A1 (en) Transgene genetic tags and methods of use
NZ745324A (en) Vaccines and vaccine components for inhibition of microbial cells
NZ702145A (en) Bluetongue virus recombinant vaccines and uses thereof
WO2009130618A3 (en) Flagellin polypeptide vaccines
SG10201808158UA (en) Site-specific glycoengineering of targeting moieties
UA112985C2 (uk) Одноланцюговий поліпептидний гібридний білок
ES2454773T3 (es) Fragmentos solubles de la proteína PB2 del virus influenza con capacidad para unirse a un casquete de ARN
NZ735684A (en) Materials and methods for respiratory disease control in canines
NZ705575A (en) Recombinant clostridium botulinum neurotoxins
WO2016130628A8 (en) Griffithsin mutants
NZ702839A (en) Vaccine and methods to reduce campylobacter infection
NZ586074A (en) LCLRP peptides, constructs and uses thereof
NZ629309A (en) Tumour necrosis factor receptor fusion proteins and methods of using the same
MX2017010359A (es) Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc).
WO2015107363A3 (en) Mycobacterial antigen composition
WO2008151633A3 (en) Vectors for vaccines against lentivirus infections
MX2023002413A (es) Proteinas de fusion inmunogenicas de coronavirus y metodos relacionados.
WO2010040847A3 (en) Recombinant protein bodies as immunogen-specific adjuvants
GB0608368D0 (en) Process for making Oligopeptides
GB2498323A (en) Generation of antigenic virus-like particles through protein-protein linkages
AR110626A1 (es) Paramixovirus y sus usos
TW201008576A (en) New fusion proteins and their use for the preparation of vaccines against hepatitis C